Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MP0533 |
Synonyms | |
Therapy Description |
MP0533 is a CD3-engaging Designed Ankyrin Repeat Protein (DARPin) that targets CD33, CD123, and CD70, potentially resulting in tumor cell killing and antitumor activity (Blood (2022) 140 (Supplement 1): 2251-2252). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MP0533 | MP-0533|MP 0533 | MP0533 is a CD3-engaging Designed Ankyrin Repeat Protein (DARPin) that targets CD33, CD123, and CD70, potentially resulting in tumor cell killing and antitumor activity (Blood (2022) 140 (Supplement 1): 2251-2252). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05673057 | Phase Ib/II | MP0533 | Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | NLD | LTU | FRA | CHE | 0 |